A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Completed · Phase 1

Conditions studied: Neoplasms, Metastases, Neoplasm

In brief

This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.

Key facts

Study ID
NCT00046423
Run by
Celgene Corporation
People needed
20
Starts
2000-04-01
Last updated by the study team
2016-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.